ClinicalTrials.gg
CompletedNCT05488301SHVUpdated Aug 31, 2023

Effects of Chest Physiotherapy in Hyperventilation Syndrome

An observational study in Hyperventilation, sponsored by Centre Hospitalier des Pays de Morlaix. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-08-31.

Sponsored by Centre Hospitalier des Pays de Morlaix · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
46
Ages
18 Years and older
Sex
All
01

Study summary

Hyperventilation syndrome induce dyspnea and altered quality of life. the aim of this study is to assess the impact of chest physiotherapy on hyperventilation syndrome' symptoms

02

Conditions studied

  • Hyperventilation

Keywords

  • hyperventilation
  • quality of life
  • dyspnea
  • Nijmegen
  • anxiety
03

In context

Hyperventilation

43 studies on the registry are indexed under Hyperventilation; 6 are open to participants now.

This study's enrollment of 46 is below the median of 54 across 11 observational studies indexed under Hyperventilation.

Browse Hyperventilation studies →

Lead sponsor

Centre Hospitalier des Pays de Morlaix is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

patients with hyperventilation syndrome adressed for chest physiotherapy

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients addressed for hyperventilation syndrome
  • patient aged 18 years or over
  • patient able to consent and having sign a consent form

Exclusion criteria

Exclusion Criteria:

  • respiratory disease (, interstitial lung disease, bronchiectasis, cystic fibrosis, uncontrolled asthma)
  • patient with an inability to complete questionaires
  • refusal of participation
  • patient under tutorship or curatorship
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
46 participants (actual)
Target follow-up
3 Months
Patient registry
Yes

Interventions

  • Otherchest physiotherapy

    chest physiotherapy session including: * nasal ventilation * decrease of respiratory rate without increasement of Tidal volume * abdomino-diaphragmatic ventilation

06

What researchers measure

Primary outcomes

  1. change of Nijmegen score

    Nijmegen score is measured at baseline and after 5 weeks. The Nijmegen questionnaire allows to assess hyperventilation symptoms. the minimum and maximum values are between 0 to 64, and higher scores mean a worse outcome.

    Time frame: 5 weeks

Secondary outcomes

  1. change of Nijmegen Score

    Nijemegen score is measured at baseline and after 1 week. The Nijmegen questionnaire allows to assess hyperventilation symptoms the minimum and maximum values are between 0 to 64, and higher scores mean a worse outcome.

    Time frame: 1 week

  2. change of Hospital Anxiety and Depression score (HAD)

    Anxiety and depression scores are measured at baseline and after 5 weeks. the minimum and maximum values are between 0 to 21 for each item (Anxiety and Depression), and higher scores mean a worse outcome.

    Time frame: 5 weeks

  3. change of Short Form-36 score (SF-36)

    SF 36 score is measured at baseline and after 5 weeks. SF36 allows to assess quality of life. the minimum and maximum values are between 0 to 100, and higher scores mean a better outcome.

    Time frame: 5 weeks

  4. change of Dyspnea-12 score

    Dyspnea-12 is measured at at baseline and after 5 weeks. Dyspnea-12 questionnaire allows to assess sensorial and emotional component of dyspnea. The minimum and maximum values are between à to 36, and higher scores mean a worse outcome.

    Time frame: 5 weeks

07

Study locations

1 site
  • BEAUMONT
    Morlaix, 29600, France
08

References and documents

Publications

  • Chenivesse C, Similowski T, Bautin N, Fournier C, Robin S, Wallaert B, Perez T. Severely impaired health-related quality of life in chronic hyperventilation patients: exploratory data. Respir Med. 2014 Mar;108(3):517-23. doi: 10.1016/j.rmed.2013.10.024. Epub 2013 Nov 7. PubMed 24269004 ↗
  • Kiesel K, Burklow M, Garner MB, Hayden J, Hermann AJ, Kingshott E, McCullough G, Ricard R, Stubblefield G, Volz J, Waskiewicz D, Englert A. EXERCISE INTERVENTION FOR INDIVIDUALS WITH DYSFUNCTIONAL BREATHING: A MATCHED CONTROLLED TRIAL. Int J Sports Phys Ther. 2020 Feb;15(1):114-125. PubMed 32089963 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 31, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05488301
Lead sponsor
Centre Hospitalier des Pays de Morlaix
Responsible party
Marc Beaumont (Principal Investigator, Centre Hospitalier des Pays de Morlaix) — Principal investigator
First posted
Aug 4, 2022
Start date
Oct 1, 2021
Primary completion
Aug 1, 2023
Completion
Aug 1, 2023
Last update
Aug 31, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion